검색어 : 통합검색[Levine Adam]
총 979건 중 979건 출력
, 97/98 페이지
-
961
- Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma
- Martin III, Thomas; Lin, Yi; Agha, Mounzer; Cohen, Adam D.; Htut, Myo; Stewart, A. Keith; Hari, Parameswaran; Berdeja, Jesus G.; Madduri, Deepu; Usmani, Saad Z.; Yeh, Tzu-Min; Allred, Alicia J.; Olyslager, Yunsi; Banerjee, Arnob; Goldberg, Jenna D.; Schecter, Jordan M.; Jackson, Carolyn C.; Deraedt, William; Gries, Katharine S.; Fastenau, John; Wu, Xiaoling; Carrasco, Marlene J.; Akram, Muhammad; Hossain, Farah; Jakubowiak, Andrzej; Jagannath, Sundar; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Division of Hematology, Mayo Clinic, Rochester, MN; UPMC Hillman Cancer Center, Pittsburgh, PA; University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA; City of Hope Comprehensive Cancer Center, Duarte, CA; UHN and the Princess Margaret Cancer Centre, Toronto, Canada; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Mount Sinai Medical Center, New York, NY; Levine Cancer Institute, Charlotte, NC; Janssen R&D, Raritan, NJ; Janssen R&D, Spring House, PA; Janssen R&D, Beerse, Belgium; Janssen R&D, Spring House, PA; Janssen R&D, Raritan, NJ; Janssen R&D, Raritan, NJ; Janssen R&D, Raritan, NJ; Janssen R&D, Beerse, Belgium; Janssen Global Services, LLC, Raritan, NJ; Janssen R&D, Raritan, NJ; Legend Biotech USA Inc., Piscataway,; (Blood, v.136, 2020, pp.41-42)
-
962
- Surgical evaluation in children <3 years of age with drug‐resistant epilepsy: Patient characteristics, diagnostic utilization, and potential for treatment delays
- Perry, Michael Scott; Shandley, Sabrina; Perelman, Max; Singh, Rani K.; Wong‐ Kisiel, Lily; Sullivan, Joseph; Gonzalez‐ Giraldo, Ernesto; Romanowski, Erin Fedak; McNamara, Nancy A.; Marashly, Ahmad; Ostendorf, Adam P.; Alexander, Allyson; Eschbach, Krista; Bolton, Jeffrey; Wolf, Steven; McGoldrick, Patricia; Depositario‐ Cabacar, Dewi F.; Ciliberto, Michael A.; Gedela, Satyanarayana; Sannagowdara, Kumar; Karia, Samir; Shrey, Daniel W.; Tatachar, Priya; Nangia, Srishti; Grinspan, Zachary; Reddy, Shilpa B.; Shital, Patel; Coryell, Jason; Justin Neuroscience Center, Cook Children’s Medical Center, Fort Worth, Texas, USA; Justin Neuroscience Center, Cook Children’s Medical Center, Fort Worth, Texas, USA; Doernbecher Children’s Hospital, Oregon Health Science Center, Oregon Health and Sciences University, Portland, Oregon, USA; Division of Neurology, Department of Pediatrics, Atrium Health/Levine Children’s Hospital, Charlotte, North Carolina, USA; Divisions of Child Neurology and Epilepsy, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; Benioff Children’s Hospital, University of California, San Francisco Weill Institute for Neurosciences, San Francisco, California, USA; Benioff Children’s Hospital, University of California, San Francisco; (Epilepsia : the journal of the International League against Epilepsy, v.63, 2022, pp.96-107)
-
963
- Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
- Melody, Megan; Grover, Natalie; Franco, Stephanie; Romancik, Jason T; Cortese, Matthew J; Moyo, Tamara K; Bhansali, Rahul S; Ollila, Thomas; Kenkre, Vaishalee P; Fitzgerald, Lindsey; Hess, Brian; Matasar, Matthew; Shouse, Geoffrey; Annunzio, Kaitlin; Herr, Megan M; Davis, James A; Jesme, Christy; Pelcovits, Ari; Moreira, Jonathan; Ma, Shuo; Winter, Jane N; Lin, Adam Yuh; Danilov, Alexey; Roy, Ishan; Barta, Stefan K.; Gordon, Leo I.; Stephens, Deborah M.; Cohen, Jonathon B; Epperla, Narendranath; Karmali, Reem; 1Feinberg School of Medicine, Northwestern University, Chicago, IL; 2University of North Carolina, Chapel Hill, NC; 3Feinberg School of Medicine, Northwestern University, Chicago, IL; 4Winship Cancer Institute, Emory University, Atlanta, GA; 5Roswell Park Comprehensive Cancer Center, Department of Medicine (Lymphoma Section), Buffalo, NY; 6Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC; 7Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; 8Brown University, Providence, RI; 9Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI; 10Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; 11Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; 12Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ; 13City of Hope Cancer Center, Duarte, CA; 14Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio St; (Blood, v.144, 2024, pp.473-473)
-
964
- Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
- Freeman, Ciara Louise; Dhakal, Binod; Kaur, Gurbakhash; Maziarz, Richard T.; Callander, Natalie; Sperling, Adam S.; Schinke, Carolina; Jakubowiak, Andrzej J; Biran, Noa; Sborov, Douglas W; Varga, Cindy; Deol, Abhinav; Kanate, Abraham S.; Koç oğ lu, Mehmet Hakan; Solh, Melhem M.; Banerjee, Kamalika; Chan, Rebecca; Nahas, Myrna; Kostic, Ana; Granados, Enrique; Jackson, Carolyn; Heery, Christopher R.; Welliver, Tim; Patel, Krina K.; Frigault, Matthew; 1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; 2Medical College of Wisconsin, Milwaukee, WI; 3Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; 4Knight Cancer Institute, Oregon Health and Science University, Portland, OR; 5University of Wisconsin, Carbone Cancer Center, Madison, WI; 6Dana-Farber Cancer Institute, Boston, MA; 7Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR; 8Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL; 9Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; 10Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; 11Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC; (Blood, v.144, 2024, pp.1031-1031)
-
965
- Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma
- Melody, Megan; Epperla, Narendranath; Shouse, Geoffrey P.; Romancik, Jason T.; Moyo, Tamara K.; Kenkre, Vaishalee P; Ollila, Thomas; Fitzgerald, Lindsey; Hess, Brian; David, Kevin A.; Annunzio, Kaitlin; Herr, Megan; Bhansali, Rahul S.; Harris, Elyse I; Davis, James A; Odetola, Oluwatobi; Lin, Adam Yuh; Moreira, Jonathan; Ma, Shuo; Winter, Jane N.; Stephens, Deborah M.; Danilov, Alexey; Shah, Nirav N.; Roy, Ishan; Barta, Stefan K.; Cortese, Matthew J; Torka, Pallawi; Cohen, Jonathon B.; Gordon, Leo I.; Karmali, Reem; 1Feinberg School of Medicine, Northwestern University, Chicago, IL; 2The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH; 3City of Hope Comprehensive Cancer Center, Duarte, CA; 4Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA; 5Atrium Health / Levine Cancer Institute, Charlotte, NC; 6Department of Medicine Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin-Madison, Madison, WI; 7Brown University, Providence, RI; 8Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; 9Medical University of South Carolina, Charleston, SC; 10Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ; 11The James Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH; 12Roswell Park Comprehensive Cancer Center, Buffalo, NY; 13Abramson Cancer Center, Hospital of; (Blood, v.142, 2023, pp.1738-1738)
-
966
- Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities
- Melody, Megan; Epperla, Narendranath; Cortese, Matthew J; Romancik, Jason T.; Moyo, Tamara K.; Kenkre, Vaishalee P; Ollila, Thomas; Fitzgerald, Lindsey; Hess, Brian; David, Kevin A.; Annunzio, Kaitlin; Herr, Megan; Bhansali, Rahul S.; Harris, Elyse I; Davis, James A; Odetola, Oluwatobi; Lin, Adam Yuh; Ma, Shuo; Moreira, Jonathan; Winter, Jane N.; Stephens, Deborah M.; Danilov, Alexey; Shah, Nirav N.; Cohen, Jonathon B.; Shouse, Geoffrey P.; Roy, Ishan; Barta, Stefan K.; Gordon, Leo I.; Karmali, Reem; 1Feinberg School of Medicine, Northwestern University, Chicago, IL; 2The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH; 3Roswell Park Comprehensive Cancer Center, Buffalo, NY; 4Winship Cancer Institute, Emory University, Atlanta, GA; 5Atrium Health / Levine Cancer Institute, Charlotte, NC; 6Department of Medicine Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin-Madison, Madison, WI; 7Brown University, Providence, RI; 8Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; 9Medical University of South Carolina, Charleston, SC; 10Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ; 11The James Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH; 3Roswell Park Comprehensive Cancer Center, Buffalo, NY; 12Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; (Blood, v.142, 2023, pp.2407-2407)
-
967
- Haploidentical Bone Marrow Transplantation for Sickle Cell Disease
- Kassim, Adetola A.; Walters, Mark C.; Eapen, Mary; Smith, Madoc; Logan, Brent R.; Solh, Melhem; McKinney, Christopher; Nieder, Michael; Ross, Maureen; Kent, Michael; Abusin, Ghada A.; Mallhi, Kanwaldeep; Silva, Jorge Galvez; Shaughnessy, Paul; Kanter, Julie; Haines, Hilary; Farah, Rafic; Khaled, Yasser A.; Ritzau, Nicole; Mendizabal, Adam; Abraham, Allistair; Bollard, Catherine; Cooke, Kenneth; de la Fuente, Josu; Hanna, Rabi; Horowitz, Mary M.; Jordan, Lori C.; Bakshi, Nitya; Krishnamurti, Lakshmanan; Leifer, Eric; Mahadeo, Kris Michael; Shenoy, Shalini; Jones, Richard J.; DeBaun, Michael R.; Brodsky, Robert A.; Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, Vanderbilt University School of Medicine, Nashville; Division of Pediatric Hematology, UCSF School of Medicine, San Francisco; Department of Medicine, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee; The Emmes Company, Rockville, MD; The Emmes Company, Rockville, MD; The Blood and Marrow Transplant Program, Northside Hospital, Atlanta; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Children’s Hospital Colorado, Aurora, CO; Blood and Marrow Transplant Department, H Lee Moffitt Cancer Center, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Atrium Health Levine Children’s Hospital, Charlotte, NC; Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI; Division of Hematology, Oncology, Bone Marrow Transplant, and Cellular Therapy, Department of Pediatrics, University of Washington, Seatt; (NEJM evidence, v.4, 2025, )
-
968
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- Berdeja, Jesus G; Madduri, Deepu; Usmani, Saad Z; Jakubowiak, Andrzej; Agha, Mounzer; Cohen, Adam D; Stewart, A Keith; Hari, Parameswaran; Htut, Myo; Lesokhin, Alexander; Deol, Abhinav; Munshi, Nikhil C; O'Donnell, Elizabeth; Avigan, David; Singh, Indrajeet; Zudaire, Enrique; Yeh, Tzu-Min; Allred, Alicia J; Olyslager, Yunsi; Banerjee, Arnob; Jackson, Carolyn C; Goldberg, Jenna D; Schecter, Jordan M; Deraedt, William; Zhuang, Sen Hong; Infante, Jeffrey; Geng, Dong; Wu, Xiaoling; Carrasco-Alfonso, Marlene J; Akram, Muhammad; Hossain, Farah; Rizvi, Syed; Fan, Frank; Lin, Yi; Martin, Thomas; Jagannath, Sundar; Sarah Cannon Research Institute, Nashville; Mount Sinai Medical Center; Levine Cancer Institute-Atrium Health; University of Chicago Medical Center; UPMC Hillman Cancer Center; Abramson Cancer Center, University of Pennsylvania; University Health Network and the Princess Margaret Cancer Centre; Department of Medicine, Medical College of Wisconsin; City of Hope Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; Karmanos Cancer Institute, Wayne State University; Dana-Farber Cancer Institute, Harvard Medical School; Massachusetts General Hospital, Harvard Medical School; Beth Israel Deaconess Medical Center, Harvard Medical School; Jansse; (The Lancet, v.398, 2021, pp.314-324)
-
969
- Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
- Ellsworth, Brandon L; Melody, Megan; Epperla, Narendranath; Grover, Natalie; Romancik, Jason T; Cortese, Matthew J; Bhansali, Rahul S; Moyo, Tamara K; Kenkre, Vaishalee P; Ollila, Thomas; Hess, Brian; Fitzgerald, Lindsey; Shouse, Geoffrey; Matasar, Matthew; Annunzio, Kaitlin; Herr, Megan M; Davis, James A; Jesme, Christy; Pelcovits, Ari; Moreira, Jonathan; Lin, Adam Yuh; Ma, Shuo; Winter, Jane N; Danilov, Alexey V.; Shah, Nirav N.; Barta, Stefan K.; Cohen, Jonathon B; Gordon, Leo I.; Stephens, Deborah M.; Karmali, Reem; 1Feinberg School of Medicine, Northwestern University, Chicago, IL; 1Feinberg School of Medicine, Northwestern University, Chicago, IL; 2Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH; 4The University of North Carolina at Chapel Hill, Chapel Hill, NC; 5Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA; 6Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY; 7Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; 8Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC; 9Carbone Cancer Center, Univ. of Wisconsin, Madison, WI; 10Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI; 11Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; 12Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; 13City of Hope Cancer Cent; (Blood, v.144, 2024, pp.612-612)
-
970
- Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
- Martin, Thomas; Usmani, Saad Z.; Berdeja, Jesú s G.; Jakubowiak, Andrzej; Agha, Mounzer; Cohen, Adam D; Hari, Parameswaran; Avigan, David; Deol, Abhinav; Htut, Myo; Lesokhin, Alexander; Munshi, Nikhil C.; O'Donnell, Elizabeth; Stewart, A. Keith; Schecter, Jordan M.; Goldberg, Jenna D.; Jackson, Carolyn C.; Yeh, Tzu-Min; Banerjee, Arnob; Allred, Alicia; Zudaire, Enrique; Deraedt, William; Madduri, Deepu; Olyslager, Yunsi; Zhou, Changwei; Pacaud, Lida; Lin, Yi; Jagannath, Sundar; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Levine Cancer Institute, Charlotte, NC; Sarah Cannon Research Institute, Nashville, TN; University of Chicago, Chicago, IL; UPMC Hillman Cancer Center, Pittsburgh, PA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Medical College of Wisconsin, Milwaukee, WI; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Comprehensive Cancer Center, City of Hope National Medical Center, Duarte, CA; Memorial Sloan Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Harvard Medical School, Boston, MA; University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Janssen R&D, Raritan, NJ; Janssen R&D, Raritan, NJ; Janssen R&D, Raritan, NJ; Janssen R&D, Raritan, NJ; Janssen R&D, Spring House, PA; Janssen R&D, Spri; (Blood, v.138, 2021, pp.549-549)
QUICK MENU
